C hronic heart failure is the inability of the left ventricle (LV) to supply the body with sufficient amounts of blood. On the cellular level, this contractile dysfunction is caused by deterioration of excitation-contraction (EC) coupling in cardiac myocytes. 1, 2 In the normal heart, Ca 2ϩ enters cardiac myocytes via L-type Ca 2ϩ channels (LTCCs) and triggers an even greater Ca 2ϩ release from the sarcoplasmic reticulum (SR). This Ca 2ϩ binds to the myofilaments to induce contraction. During diastole, Ca 2ϩ is taken back up into the SR by the SR Ca 2ϩ ATPase (SERCA), and the amount of Ca 2ϩ that entered the cell via LTCC is exported via the Na ϩ /Ca 2ϩ exchanger. In myocytes of failing hearts, SR Ca 2ϩ load is reduced as a result of decreased SERCA activity and a leak of the Ca 2ϩ release channels in the SR, the ryanodine receptors. Furthermore, expression and activity of the Na ϩ /Ca 2ϩ exchanger are elevated in failing myocardium, which further decreases SR Ca 2ϩ load by removing Ca 2ϩ from the cytosol during diastole. 2
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In response to decreased LV function, neurohormonal activation sustains cardiac output and blood pressure. In particular, sympathetic activation increases the local release of norepinephrine in the heart and of epinephrine from the adrenal glands. Norepinephrine binds to cardiac ␤-adrenergic receptors (␤-ARs), which couple to the stimulatory G protein (G s ) and induce the dissociation of the ␣-subunit from the ␤␥-subunits of G s . 3 The former stimulates adenylyl cyclase to produce the second messenger cAMP, activating protein kinase A, which then phosphorylates LTCC, ryanodine receptors, phospholamban (inhibiting SERCA), and troponin I. This increases Ca 2ϩ influx via LTCCs, Ca 2ϩ uptake into the SR via SERCA, and Ca 2ϩ release from the SR via ryanodine receptors, increasing the rate and amplitude of cytosolic Ca 2ϩ transients and contraction of the cell. 3 After dissociation from G s␣ , the G ␤␥ -subunits bind to the G-protein-coupled receptor kinase 2 (GRK2), also known as ␤-AR kinase 1 (␤-ARK1). GRK2 then associates with phosphoinositide 3-kinase ␥ and phosphorylates ␤-ARs, priming the binding of ␤-arrestin to the receptor, which inhibits the coupling of ␤-ARs to G s . This uncoupling of ␤-ARs turns off the signal within seconds to minutes, 4 a process called homologous desensitization. 3 With continued ␤-AR stimulation, ␤-ARs are removed from the cell surface by internalization in clathrin-coated pits, which is called ␤-AR downregulation. 3 The positive inotropic, lusitropic, and chronotropic effects of acute ␤-AR activation mediate an increase in cardiac output, which is beneficial in the short term in the context of a physiological increase in workload (ie, during exercise). In response to reduced cardiac output in heart failure, however, the sympathetic nervous system is chronically activated, which desensitizes and downregulates cardiac ␤-ARs, rendering the heart refractory to catecholamine stimulation. 5 Because the degree of sympathetic activation is related to an adverse outcome of patients with heart failure, it was perceived that ␤-AR downregulation was a major mechanism for reduced LV function in heart failure. 6 However, the observation that cardiomyocyte-specific overexpression of ␤ 1 -ARs 7 induces dilated cardiomyopathy indicated that continuous ␤ 1 -AR signaling (rather than the desensitization of this signaling pathway) accounts for maladaptive remodeling involving protein kinase A-dependent 8 and/or -independent pathways. 9 Accordingly, treatment of patients with heart failure with ␤-AR antagonists (␤-blockers) improves LV ejection fraction, clinical symptoms, and survival in patients with heart failure. 5 Although treatment with metoprolol or carvedilol led to similar improvements of prognosis, 5 only treatment with metoprolol, but not carvedilol, increased the expression of cardiac ␤ 1 -ARs in failing hearts, 10 presumably related to differential binding characteristics of these ␤-blockers to cardiac ␤-ARs. 11, 12 In fact, ␤-blockade is more complete with long-term carvedilol compared with metoprolol treatment in patients with heart failure. 13 These data support the notion that the resensitization of ␤-AR signaling per se may not be the key mechanism by which the biology of the failing heart is improved. 5 Although carvedilol does not resensitize cardiac ␤-ARs, it has in common with first-and second-generation ␤-blockers that it downregulates GRK2, whereas agonist stimulation of ␤-ARs upregulates GRK2, 14 in agreement with upregulated GRK2 in failing human hearts. 15 Considering the reciprocal association between GRK2 expression and the early perception that resensitization of ␤-AR signaling may be key to improve overall cardiac function in heart failure, Koch et al 16 pioneered a transgenic strategy to inhibit elevated GRK2 activity by overexpressing a peptide corresponding to the G ␤␥ -interacting C-terminal domain of ␤-ARK1 called ␤ARKct. Interestingly, this peptide not only resensitized ␤-AR signaling but also rescued several small-and largeanimal models of heart failure. 17, 18 It is still controversial, however, whether the beneficial effects of ␤ARKct are indeed related to resensitization of ␤-AR signaling by inhibiting GRK2 or to the scavenging of G ␤␥ subunits by ␤ARKct that may exert other, GRK2-independent (maladaptive) structural or functional remodeling. 17, 19 In this respect, recent data from the Koch and Dorn laboratories supported the importance of GRK2 inhibition by improving cardiac function and survival after myocardial infarction by genetic postnatal deletion of cardiac GRK2. 4, 20 Despite a great wealth of data on the effects of ␤ARKct on ␤-adrenergic signaling and cardiac remodeling, surprisingly little information has been available on how ␤ARKct or GRK2 deletion affects the actual underlying deficit in heart failure, ie, deteriorated EC coupling. In this issue of Circulation, Raake et al 21 provide an elaborate mechanistic study that for the first time characterizes GRK2-deficient cardiac myocytes. Despite unchanged steady-state Ca 2ϩ transients at baseline, the SR Ca 2ϩ load is decreased in GRK2-deficient myocytes, whereas the fractional SR Ca 2ϩ release during steady-state Ca 2ϩ transients is increased. This increase in the fractional SR Ca 2ϩ release can be explained by elevated open probability and currents of the LTCC secondary to constitutive protein kinase A-mediated phosphorylation of LTCC. The authors relate this to elevated constitutive activity of ␤-ARs in the absence of any GRK2-mediated phosphorylation. Because Ca 2ϩ influx must match Ca 2ϩ efflux, upregulation of Na ϩ / Ca 2ϩ exchanger protein and currents apparently counterbalances the increase in LTCC-mediated Ca 2ϩ influx. On the other hand, decreased SR Ca 2ϩ load was associated with decreased phospholamban phosphorylation in GRK-deficient myocytes, which could be reversed by the PDE4 inhibitor rolipram. This is in agreement with the observation that PDE4 associates with-and controls the activity of-SERCA but not LTCC in murine cardiac myocytes. 22 Interestingly, besides the well-characterized activation of PDE4 by protein kinase A-mediated phosphorylation, 23 SR-associated PDE4 is also under the control of phosphoinositide 3-kinase ␥ in cardiac myocytes, 24 which suggests a close interplay between GRK2, phosphoinositide 3-kinase ␥, and PDE4 to constitutively control local cAMP pools near the SR. The details of this complex interplay await further elucidation.
Despite reduced baseline phosphorylation of phospholamban, ␤-AR agonist-induced phosphorylation of phospholamban was potentiated in GRK2-deficient myocytes, in line with the notion that in normal myocytes GRK2 rapidly uncouples ␤-ARs from G s on agonist-induced receptor activation, 4 reducing downstream ␤-AR signaling. 3 Accordingly, SR Ca 2ϩ load was potentiated after ␤-adrenergic stimulation in GRK2-deficient myocytes compared with controls. This is in line with the sensitized ␤-AR signaling observed in GRK2deficient mouse hearts in vivo. 4 In a previous study, 20 Raake et al observed that GRK2 deletion improved LV function and survival after myocardial infarction. Extending these results to the cellular levels, Raake et al 21 here relate this improved LV function to maintained SR Ca 2ϩ load, Na ϩ /Ca 2ϩ exchanger, and LTCC currents, preserving EC coupling compared with shamoperated GRK2-deficient animals. This contrasts with the maladaptive remodeling of EC coupling in wild-type animals after myocardial infarction, ie, reduced SR Ca 2ϩ load, presumably as a result of upregulated Na ϩ /Ca 2ϩ exchanger activity, and downregulated LTCC current density, alterations that can also be found in the failing human heart. 2 Together, these data suggest that GRK2 plays a key role in the maladaptive remodeling processes that deteriorate EC coupling on a cellular level; thus, targeting GRK2 may be an attractive approach to ameliorate the development of contractile dysfunction in heart failure.
Despite these appealing novel results, a number of issues remain unresolved that can stimulate further research in this important and clinically relevant area. For instance, why does the phenotype of GRK2 deletion differ profoundly from the recently characterized EC coupling phenotype after ␤ARKct overexpression 25 ? In the latter, the only change of EC coupling that could be observed was ␤ARKct-mediated relief of G ␤␥ -induced inhibition of LTCC, supporting the earlier idea that ␤ARKct mediates its beneficial effects via G ␤␥ scavenging rather than GRK2 inhibition. 19 One would have expected that ␤ARKct should share some (if not all) effects of GRK2 deletion (or vice versa) plus the G ␤␥ -scavenging effects. Furthermore, in an earlier study on the same GRK2deficient mice, 4 constant ␤-adrenergic stimulation in vivo aggravated contractile dysfunction and maladaptive remodeling despite (or rather because of) a restoration of ␤-AR signaling, whereas after myocardial infarction, GRK2deficient mice had ameliorated structural and functional remodeling. 20, 21 One way to address these issues is to combine ␤ARKct expression with GRK2 deletion, which should give further insight into the complex interplay of receptor regulation and EC coupling processes revealed by the present study.
In conclusion, the authors are to be congratulated on a rigorous and detailed characterization of GRK2-related regulation of EC coupling, which, in the face of the aching absence of data to this point, is a timely issue. From a clinical point of view, the study supports the notion that restoring (or maintaining) the physiological processes of EC coupling after cardiac stress (in this case, myocardial infarction) is an attractive approach to ameliorate the development of heart failure. In this context, it is important to note that also in ␤-blocker-treated patients, restoration of SERCA but not ␤ 1 -AR expression was associated with a clinical improvement in these patients. 26 The fact that in animal studies the beneficial effect of ␤ARKct was additive to the effect of the ␤-blocker metoprolol encourages us to continue translational efforts, pioneered by the same group, 18 to bring ␤ARKct gene therapy eventually to the clinical arena. 17 Finally, the encouraging data of the recent phase II Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial 27 with intracoronary gene therapy of SERCA lend further support to the concept of targeting defective EC coupling in patients with heart failure.
